PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(01): 47-52
DOI: 10.4103/0971-5851.177030
ORIGINAL ARTICLE

Fluorodeoxyglucose-positron emission tomography in carcinoma nasopharynx: Can we predict outcomes and tailor therapy based on postradiotherapy fluorodeoxyglucose-positron emission tomography?

Sarbani Ghosh Laskar
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Gunjan Baijal
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Venkatesh Rangarajan
Department of Bio-Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Nilendu Purandare
Department of Bio-Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Manju Sengar
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Sneha Shah
Department of Bio-Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Tejpal Gupta
Advanced Centre for Treatment Research and Education in Cancer, Mumbai, Maharashtra, India
,
Ashwini Budrukkar
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vedang Murthy
Advanced Centre for Treatment Research and Education in Cancer, Mumbai, Maharashtra, India
,
Prathamesh Pai
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
A K D′Cruz
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
J P Agarwal
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
  als PDF herunterladen Lizenzen und Reprints

Abstract

Background: Positron emission tomography-computed tomography (PET-CT) is an emerging modality for staging and response evaluation in carcinoma nasopharynx. This study was conducted to evaluate the impact of PET-CT in assessing response and outcomes in carcinoma nasopharynx. Materials and Methods: Forty-five patients of nonmetastatic carcinoma nasopharynx who underwent PET-CT for response evaluation at 10-12 weeks posttherapy between 2004 and 2009 were evaluated. Patients were classified as responders (Group A) if there was a complete response on PET-CT or as nonresponders (Group B) if there was any uptake above the background activity. Data regarding demographics, treatment, and outcomes were collected from their records and compared across the Groups A and B. Results: The median age was 41 years. 42 out of 45 (93.3%) patients had WHO Grade 2B disease (undifferentiated squamous carcinoma). 24.4%, 31.1%, 15.6, and 28.8% patients were in American Joint Committee on Cancer Stage IIb, III, Iva, and IVb. All patients were treated with neoadjuvant chemotherapy followed by concomitant chemoradiotherapy. Forty-five patients, 28 (62.2%) were classified as responders, whereas 17 (37.8%) were classified as nonresponders. There was no significant difference in the age, sex, WHO grade, and stage distribution between the groups. Compliance to treatment was comparable across both groups. The median follow-up was 25.3 months (759 days). The disease-free survival (DFS) of the group was 57.3% at 3 years. The DFS at 3 years was 87.3% and 19.7% for Group A and B, respectively (log-rank test, P < 0.001). Univariate and multivariate analysis revealed Groups to be the only significant factor predicting DFS (P value 0.002 and < 0.001, respectively). In Group B, the most common site of disease failure was distant (9, 53%). Conclusion: PET-CT can be used to evaluate response and as a tool to identify patients at higher risk of distant failure. Further, this could be exploited to identify patients who may need treatment intensification. This needs to be validated prospectively.

Keywords

Carcinoma nasopharynx - positron emission tomography-computed tomography - predictive value - response evaluation


Publikationsverlauf

Artikel online veröffentlicht:
12. Juli 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer Incidence in Five Continents. IARC Scientific Publications No. 155. Vol. VIII. Lyon: IARC; 2002.
  • 2 National Cancer Registry Programme: First All India Report. Available from: . [Last accessed on 2011 Nov].
  • 3 Yen RF, Hung RL, Pan MH, Wang YH, Huang KM, Lui LT, et al. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003;98:283-7.
  • 4 Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22.
  • 5 Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9.
  • 6 Ghosh-Laskar S, Agarwal JP, Mohindra P, Sengar M, Vyas S, Pai VR, et al. Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: Evaluation of its role as neoadjuvant chemotherapy. Med Oncol 2009;26:393-401.
  • 7 Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
  • 8 Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J Clin Oncol 2004;22:4604-12.
  • 9 Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. J Clin Oncol 2004;22:2643-53.
  • 10 Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, Chong LM, Shaha AR, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1105-10.
  • 11 Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
  • 12 Franchin G, Vaccher E, Talamini R, Politi D, Gobitti C, Minatel E, et al. Intensity-modulated radiotherapy (IMRT)/tomotherapy following neoadjuvant chemotherapy in stage IIB-IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. Oral Oncol 2011;47:905-9.
  • 13 Lee AW, Perez CA. Nasopharynx. Principles and Practice of Radiation Oncology. 5 th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 821-32.
  • 14 Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
  • 15 Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9.
  • 16 Kwong DL, Nicholls J, Wei WI, Chua DT, Sham JS, Yuen PW, et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer 1999;85:1446-53.
  • 17 Chan SC, Chang JT, Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncol 2009;45:52-8.
  • 18 Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211-6.
  • 19 Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44.
  • 20 Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
  • 21 Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33:569-77.